Cbd and Metoprolol
Supplement–drug interaction evidence from the TruthStack database.
| Severity | HIGH |
|---|---|
| Evidence Tier | Limited |
| Interaction Type | PHARMACODYNAMIC RISK |
| Mechanism | PHARMACODYNAMIC |
| Last Reviewed | 2026-02-10 |
Summary
Monitor closely. 161 serious adverse events reported with this combination in FDA FAERS. Pharmacovigilance signal, not proof of causation. Discuss with prescriber.
CYP Enzyme Pathway Overlap
Cbd and Metoprolol share activity on the following CYP enzymes:
| Enzyme | Cbd | Metoprolol |
|---|---|---|
| CYP2D6 | INHIBITOR (MODERATE) | SUBSTRATE (STRONG) |
Shared Pharmacodynamic Endpoints
Both compounds influence the same physiological endpoints in the same direction:
| Endpoint | Direction | Cbd | Metoprolol |
|---|---|---|---|
| CNS DEPRESSION | INCREASE | MODERATE | WEAK |
Cumulative effect on shared endpoints may exceed individual compound profiles. This is relevant to discussion with a prescribing clinician.
What We Don't Know
This interaction has limited evidence. Key gaps may include: direct clinical trial data for this specific combination, dose-response relationships, and long-term outcome data. Absence of evidence is not evidence of absence.
API Reference
Open, unauthenticated. Returns JSON. Developer documentation